SAB Biotherapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2020 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
SAB Biotherapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2020 to Q4 2023.
  • SAB Biotherapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $19.2M, a 55.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $19.2M +$6.89M +55.9% Dec 31, 2023 10-K 2024-03-29
Q4 2022 $12.3M +$7.03M +133% Dec 31, 2022 10-K 2024-03-29
Q4 2021 $5.3M +$2.98M +128% Dec 31, 2021 10-K/A 2023-04-28
Q4 2020 $2.32M Dec 31, 2020 10-K/A 2023-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.